Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine C. Smith(University of California, San Francisco), Neil P. Shah(University of California, San Francisco), Elisabeth A. Lasater(Palmetto Hematology Oncology), Martin Carroll(University of Pennsylvania), Scott C. Kogan(University of California, San Francisco), Alexander E. Perl(University of Pennsylvania), John Kuriyan(Vanderbilt University), Whitney Stewart(Palmetto Hematology Oncology), Grace R. Jeschke(Georgetown University), Qi Wang(NSF NCAR High Altitude Observatory), Kimberly C. Lin(Palmetto Hematology Oncology), Melissa Q. McCreery(University of California, San Francisco), Lauren E. Damon(University of California, San Francisco), Mayumi Sugita(Cornell University)
Cited by 211